Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line

Executive Summary

FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products

You may also be interested in...



Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel

FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.

Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner

Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board

Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner

Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board

Related Content

UsernamePublicRestriction

Register

PS048046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel